Literature DB >> 16775370

Molecular genetics of X-linked Charcot-Marie-Tooth disease.

Kleopas A Kleopa1, Steven S Scherer.   

Abstract

The X-linked form of Charcot-Marie-Tooth disease (CMT1X) is the second most common molecularly designated form of hereditary motor and sensory neuropathy. The clinical phenotype is characterized by progressive distal muscle atrophy and weakness, areflexia, and variable sensory abnormalities. Affected males have moderate-to-severe symptoms, whereas heterozygous females are usually mildly affected or even asymptomatic. Several patients also have manifestations of central nervous system involvement or hearing impairment. Electrophysiological and pathological studies of peripheral nerves show evidence of demyelinating neuropathy with prominent axonal degeneration. A large number of mutations in the GJB1 gene encoding the gap junction (GJ) protein connexin32 (Cx32) cause CMT1X. Cx32 is expressed by Schwann cells and oligodendrocytes, as well as by other tissues, and the GJ formed by Cx32 play an important role in the homeostasis of myelinated axons. The reported CMT1X mutations are diverse and affect both the promoter region as well as the coding region of GJB1. Many Cx32 mutants fail to form functional GJ, or form GJ with abnormal biophysical properties. Furthermore, Cx32 mutants are often retained intracellularly either in the endoplasmic reticulum or Golgi in which they could potentially have additional dominant-negative effects. Animal models of CMT1X demonstrate that loss of Cx32 in myelinating Schwann cells causes a demyelinating neuropathy. No definite phenotype-genotype correlation has yet been established for CMT1X and effective molecular based therapeutics for this disease, remain to be developed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775370     DOI: 10.1385/nmm:8:1-2:107

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  111 in total

Review 1.  Structural and functional diversity of connexin genes in the mouse and human genome.

Authors:  Klaus Willecke; Jürgen Eiberger; Joachim Degen; Dominik Eckardt; Alessandro Romualdi; Martin Güldenagel; Urban Deutsch; Goran Söhl
Journal:  Biol Chem       Date:  2002-05       Impact factor: 3.915

2.  Macrophage-related demyelination in peripheral nerves of mice deficient in the gap junction protein connexin 32.

Authors:  Igor Kobsar; Mathias Mäurer; Thomas Ott; Rudolf Martini
Journal:  Neurosci Lett       Date:  2002-03-01       Impact factor: 3.046

Review 3.  Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients.

Authors:  Naoki Hattori; Masahiko Yamamoto; Tsuyoshi Yoshihara; Haruki Koike; Masanori Nakagawa; Hiroo Yoshikawa; Akio Ohnishi; Kiyoshi Hayasaka; Osamu Onodera; Masayuki Baba; Hitoshi Yasuda; Toyokazu Saito; Kenji Nakashima; Jun-ichi Kira; Ryuji Kaji; Nobuyuki Oka; Gen Sobue
Journal:  Brain       Date:  2003-01       Impact factor: 13.501

4.  Linkage analyses between dominant X-linked Charcot-Marie-Tooth disease, and 15 Xq11-Xq21 microsatellites in a new large family: three new markers are closely linked to the gene.

Authors:  E Le Guern; N Ravise; M Gugenheim; A Vignal; C Penet; P Bouche; J Weissenbach; Y Agid; A Brice
Journal:  Neuromuscul Disord       Date:  1994 Sep-Nov       Impact factor: 4.296

5.  Clinical phenotype in X-linked Charcot-Marie-Tooth disease with an entire deletion of the connexin 32 coding sequence.

Authors:  M Nakagawa; H Takashima; F Umehara; K Arimura; F Miyashita; N Takenouchi; W Matsuyama; M Osame
Journal:  J Neurol Sci       Date:  2001-03-15       Impact factor: 3.181

6.  X-linked dominant Charcot-Marie-Tooth neuropathy: clinical, electrophysiological, and morphological phenotype in four families with different connexin32 mutations(1).

Authors:  J Senderek; B Hermanns; C Bergmann; B Boroojerdi; M Bajbouj; M Hungs; V T Ramaekers; S Quasthoff; D Karch; J M Schröder
Journal:  J Neurol Sci       Date:  1999-08-15       Impact factor: 3.181

7.  Connexins are critical for normal myelination in the CNS.

Authors:  Daniela M Menichella; Daniel A Goodenough; Erich Sirkowski; Steven S Scherer; David L Paul
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

8.  Unique distributions of the gap junction proteins connexin29, connexin32, and connexin47 in oligodendrocytes.

Authors:  Kleopas A Kleopa; Jennifer L Orthmann; Alan Enriquez; David L Paul; Steven S Scherer
Journal:  Glia       Date:  2004-09       Impact factor: 7.452

9.  Localization of X-linked dominant Charcot-Marie-Tooth disease (CMT 2) to Xq13.

Authors:  J Beckett; J J Holden; N E Simpson; B N White; P M MacLeod
Journal:  J Neurogenet       Date:  1986-07       Impact factor: 1.250

10.  Sex-linked recessive inheritance in Charcot-Marie-tooth disease with partial clinical manifestations in female carriers.

Authors:  J P Fryns; H Van den Berghe
Journal:  Hum Genet       Date:  1980       Impact factor: 4.132

View more
  36 in total

1.  GJB1/Connexin 32 whole gene deletions in patients with X-linked Charcot-Marie-Tooth disease.

Authors:  Claudia Gonzaga-Jauregui; Feng Zhang; Charles F Towne; Sat Dev Batish; James R Lupski
Journal:  Neurogenetics       Date:  2010-06-09       Impact factor: 2.660

2.  The role of gap junctions in Charcot-Marie-Tooth disease.

Authors:  Kleopas A Kleopa
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

3.  Inflammatory demyelinating CNS disorder in a case of X-linked Charcot-Marie-Tooth disease: positive response to natalizumab.

Authors:  Jochen H Weishaupt; Claudia Ganser; Mathias Bähr
Journal:  J Neurol       Date:  2012-03-13       Impact factor: 4.849

4.  Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.

Authors:  Natalie Vavlitou; Irene Sargiannidou; Kyriaki Markoullis; Kyriacos Kyriacou; Steven S Scherer; Kleopas A Kleopa
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

Review 5.  Oligodendroglia: metabolic supporters of axons.

Authors:  Brett M Morrison; Youngjin Lee; Jeffrey D Rothstein
Journal:  Trends Cell Biol       Date:  2013-08-27       Impact factor: 20.808

Review 6.  Connexins, pannexins, innexins: novel roles of "hemi-channels".

Authors:  Eliana Scemes; David C Spray; Paolo Meda
Journal:  Pflugers Arch       Date:  2008-10-14       Impact factor: 3.657

7.  Classification and diagnosis of the inherited neuropathies.

Authors:  Mary M Reilly
Journal:  Ann Indian Acad Neurol       Date:  2009-04       Impact factor: 1.383

8.  Exome Sequence Analysis Suggests that Genetic Burden Contributes to Phenotypic Variability and Complex Neuropathy.

Authors:  Claudia Gonzaga-Jauregui; Tamar Harel; Tomasz Gambin; Maria Kousi; Laurie B Griffin; Ludmila Francescatto; Burcak Ozes; Ender Karaca; Shalini N Jhangiani; Matthew N Bainbridge; Kim S Lawson; Davut Pehlivan; Yuji Okamoto; Marjorie Withers; Pedro Mancias; Anne Slavotinek; Pamela J Reitnauer; Meryem T Goksungur; Michael Shy; Thomas O Crawford; Michel Koenig; Jason Willer; Brittany N Flores; Igor Pediaditrakis; Onder Us; Wojciech Wiszniewski; Yesim Parman; Anthony Antonellis; Donna M Muzny; Nicholas Katsanis; Esra Battaloglu; Eric Boerwinkle; Richard A Gibbs; James R Lupski
Journal:  Cell Rep       Date:  2015-08-06       Impact factor: 9.423

9.  Human oligodendrocytes express Cx31.3: function and interactions with Cx32 mutants.

Authors:  Irene Sargiannidou; Meejin Ahn; Alan D Enriquez; Alejandro Peinado; Richard Reynolds; Charles Abrams; Steven S Scherer; Kleopas A Kleopa
Journal:  Neurobiol Dis       Date:  2008-02-15       Impact factor: 5.996

10.  Cx29 and Cx32, two connexins expressed by myelinating glia, do not interact and are functionally distinct.

Authors:  Meejin Ahn; Jonathan Lee; Andreas Gustafsson; Alan Enriquez; Eric Lancaster; Jai-Yoon Sul; Philip G Haydon; David L Paul; Yan Huang; Charles K Abrams; Steven S Scherer
Journal:  J Neurosci Res       Date:  2008-04       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.